Miceli R, Eriksson H, Lo Russo G, Alfieri S, Moksnes Bjaanæs M, Pietrantonio F, De Cecco L, Prelaj A, Proto C, Franzén J, McDonnell D, Berenguer Pina JJ, Beninato T, Mazzeo L, Giannatempo P, Verzoni E, Crown J, Helland Å, Eustace A(2024) Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study Acta Oncol, 63, 213-219 DOI 10.2340/1651-226X.2024.24179, PubMed 38647024
Brativnyk A, Ankill J, Helland Å, Fleischer T(2024) Multi-omics analysis reveals epigenetically regulated processes and patient classification in lung adenocarcinoma Int J Cancer(in press) DOI 10.1002/ijc.34915, PubMed 38489486
Haakensen VD, Öjlert ÅK, Thunold S, Farooqi S, Nowak AK, Chin WL, Grundberg O, Szejniuk WM, Cedres S, Sørensen JB, Dalen TS, Lund-Iversen M, Bjaanæs M, Helland Å(2024) UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial Eur J Cancer, 202, 113973 DOI 10.1016/j.ejca.2024.113973, PubMed 38447379
